LIMES Schlosskliniken stock
LIK.DEXETRALIMES Schlosskliniken AG, HealthcareISIN DE000A0JDBC7WKN A0JDBC
73Score 73 out of 100, Strong
Price and trend
81 / 100
Price history
+71% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 71).
The price is at its 52-week high. Largest decline in 8 years: 36% (July 2023 to October 2023).
Chart figures for advanced users
- SMA 50$596.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$579.71
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$351.61
- The lowest closing price of the last twelve months.
- Resistance$656.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LIMES Schlosskliniken AG belongs to the Medical (Care Facilities) industry (Germany) and, with a market value of $195.6M, is number 56 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $55.63M (up 33.5% year on year) and earnings of $6.34M (up 83%).
- MEQIRI Score 73 out of 100 (Strong): rank 99 of 714 in Healthcare, median 53.
Show more
- The P/E is 31.9 (Medical (Care Facilities) median 19.4, own median of recent years 22.3).
- Our model puts fair value at $241.51, with the price 165% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 35.3% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 70
- High return on capitalReturn on invested capital 30.9% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 76
- Earnings turn into cashFree cash flow 113% of earnings over the last 12 months.Fundamentals 70
Weaknesses
- Above fair valuePrice 165% above the fair value of $241.51.Valuation 47
- Richly valuedP/E 31.9, Medical (Care Facilities) median 19.4, own median 22.3.Valuation 47
Its standout strengths are momentum and stability, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 72 to 73.
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $172.51 and expensive above $402.52 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $84.90 (cash-flow model) and $398.12 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $234.65, at 6.1% it would be $251.79.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 35.5% on the twelve months before. Revenue has grown strongly since 2017, at around 29% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 38%, operating 19%, net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 17 May 2027in 186 days
- Last reported
- 31 Aug 2026EPS reported $11.67
Analyst estimates
Earnings estimates have barely changed since 25 Oct 2026.
- Earnings per share
- $31.440.0%
- Revenue
- $70.99M0.0%
- Earnings per share
- $57.420.0%
- Revenue
- $95.47M0.0%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at LIMES Schlosskliniken
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 73
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger companies by market value
- GMR SolutionsGMRS $635.3M57
- Strata Critical MedicalSRTA $536.81M47
- Starling OncologySTLN $419.93M26
- M1 KlinikenM12.DE $402.19M74
- AunaAUNA $347.12M43
- Viemed HealthcareVMD $345.96M65
- Community Health SystemsCYH $322.95M34
- MediclinMED.DE $285.41M61
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.